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Life-sustaining treatment for patients with
end-stage renal disease became a reality in 1943
when Kolff1 developed extracorporeal hemodialy-
sis. The application of this technology has been
limited because of unreliable chronic access to the
circulatory system. The Quinton-Scribner external
arteriovenous shunt provided the first dependable
angioaccess in 1960, but it was plagued by throm-
bosis and infection.2-5 In 1966, Brescia et al6 anas-
tomosed the cephalic vein to the radial artery and
introduced the autogenous arteriovenous fistula.
This fistula allowed reliable chronic angioaccess,
had low rates of infection, and was highly
durable.3-18 Today, it remains the gold standard by
which all other forms of chronic dialysis hemoac-
cess are measured.
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Objective: Angioaccess for hemodialysis in an extremity with disadvantaged venous out-
flow has reduced long-term patency. We hypothesized that arteriovenous bridge graft
patency could be improved in patients with disadvantaged venous outflow by preopera-
tive venous duplex mapping.
Methods: The charts of 114 patients who underwent 115 prosthetic arteriovenous bridge
grafts were reviewed. Disadvantaged venous outflow was defined on the basis of any
combination of prior arteriovenous bridge graft, multiple venipunctures, and clinical
examination. Patients were grouped according to the presence or absence of disadvan-
taged venous outflow. Three groups were analyzed: those with normal venous outflow
who had an initial arteriovenous bridge graft (NML), those with disadvantaged venous
outflow who had only a clinical examination before redo arteriovenous bridge graft
(REDO/DVO), and those with disadvantaged venous outflow who underwent preop-
erative duplex scanning venous evaluation (MAP/DVO). Life table primary and sec-
ondary 12-month patency rates were compared by means of log-rank analysis.
Results: Life table analysis yielded 6-month primary patency rates of 65.9% ± 5.7%,
66.4% ± 7.3%, and 43.8% ± 10.9% for NML, MAP/DVO, and REDO/DVO, respec-
tively. The secondary patency rates at 6 months for NML (91.9% ± 3.4%) and
MAP/DVO (91.1% ± 4.9%) were statistically equivalent, and both were significantly
better than the patency for REDO/DVO (75.0% ± 10.0%; P = .004 and P = .04, respec-
tively). This trend persisted beyond 12 months.
Conclusion: Preoperative evaluation of venous anatomy in patients with disadvantaged
venous outflow results in an arteriovenous bridge graft patency comparable to that seen
in patients undergoing initial arteriovenous bridge grafts. Vein mapping improves arte-
riovenous bridge graft durability in the patient with disadvantaged venous outflow by
allowing the surgeon to select venous return that is in direct continuity with the central
venous system. (J Vasc Surg 2000;32:997-1005.)
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One of the major problems of the Brescia-
Cimino fistula was venous quality. Often, veins were
not considered suitable for fistula creation, or their
subsequent maturation (thickening and dilation)
was not satisfactory.7,16,18 These problems were cir-
cumvented by the prosthetic arteriovenous bridge
graft (AVBG). This easily cannulated conduit was
ready for use within 2 weeks of implantation and
rapidly became the most common type of angioac-
cess.4,8,11,19,20 Unfortunately, AVBGs were associat-
ed with increased rates of thrombotic and infectious
complications. Shorter intervals between access
placement and revision and increasing expenditures
for such revisions have fueled an effort by the
National Kidney Foundation Dialysis Outcomes
Quality Initiative to increase the percentage of
patients with autogenous fistulae.21
Recent dialysis access surgery investigations
have focused on the use of autogenous alternatives
to the Cimino fistula, such as the brachiocephalic
fistula and the brachiobasilic fistula.9,12 Investi-
gators have used preoperative duplex scanning to
guide the selection of veins in the creation of opti-
mal forearm arteriovenous fistulae.9,12,22 We
hypothesized that preoperative venous duplex
scanning might be of use in directing the con-
struction of prosthetic AVBGs.
MATERIALS AND METHODS
Data collection. The office charts and operative
reports pertaining to 114 consecutive angioaccess
patients who underwent placement of AVBGs
between July 1, 1997, and May 31, 1998, were
reviewed. Age, sex, diabetic status, and evidence of
significant upper extremity arterial disease (upper
extremity effort discomfort or a 15-mm Hg pressure
gradient from brachial artery to forearm artery)
were noted. AVBG data included arterial and venous
anastomotic location, graft material and size,
extremity side, primary or secondary graft place-
ment, date of creation, date of first graft failure (pri-
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Fig 1. Primary patencies for NML, MAP/DVO, and REDO/DVO groups.
Table I. Demographics
Patient Average Diabetic Male Female
group age (y) (%) (%) (%)
NML 63.7 29 (45) 36 (56) 28 (44)
MAP/DVO 63.1 15 (44) 14 (41) 20 (59)
REDO/DVO 57.1 10 (63) 9 (56) 7 (44)
All groups were compared through use of χ2 analysis; P < .05 for
significance.
Table II. Outflow tracts used in conjunction with
brachial artery inflow
NML (%) MAP/DVO (%) REDO/DVO (%)
Vein n = 59 n = 32 n = 16
Median cubital 30 (51) 6 (19) 3 (19)
Axillary – – 1 (6)
Basilic 16 (27) 7 (22) 3 (19)
Brachial 8 (14) 15 (47) 4 (25)
Cephalic 5 (8) 4 (12) 4 (25)
Subclavian – – 1 (6)
Deep 8 (14) 15 (47) 6 (37)
Superficial 51 (86) 17 (53) 10 (63)
mary patency), date of ultimate graft failure (sec-
ondary patency), and date of death (survival).
Definitions and patient population. Patients
were categorized on the basis of venous outflow.
Those with disadvantaged venous outflow (DVO)
were identified on the basis of any combination of
prior AVBG in the same arm, history of multiple
venipunctures (associated with an immediately pre-
ceding protracted hospital course of > 3 weeks),
and clinical examination revealing no evidence of
superficial upper extremity veins. All patient evalu-
ations and examinations were performed by the
attending surgeon.
The patients with DVO were divided into two
groups: those who had only clinical examination (the
REDO/DVO group) and those who had both clinical
examination and preoperative duplex scan imaging
before AVBG creation (the MAP/DVO group). All of
the patients in the REDO/DVO group had previous
failed angioaccess in the ipsilateral extremity. In the
MAP/DVO group, 8 patients were entered because of
protracted hospitalization, 9 patients because of prior
ipsilateral AVG, and 17 patients because of the find-
ings of the clinical examination. Patients with normal
clinical evaluation findings before their initial AVBGs
were categorized as normal (the NML group).
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Fig 2. Secondary patencies for NML, MAP/DVO, and REDO/DVO groups.
Fig 3. Primary patencies for superficial vein versus deep vein outflow in MAP/DVO group.
A total of 115 procedures were performed in 114
patients. There were 64 procedures in 64 patients in
the NML group, 35 procedures in 34 patients in the
MAP/DVO group, and 16 procedures in 16 patients
in the REDO/DVO group. The three groups were
similar with respect to average age, sex distribution,
and incidence of diabetes (Table I).
Duplex scanning and operative technique.
Duplex scan imaging of the upper extremity venous
anatomy was performed at a single laboratory (accred-
ited by the Intersocietal Commission for the
Accreditation of Vascular Laboratories) through use of
either an ATL HDI 3000 scanner (Advanced
Technologies Laboratories, Bothell, Wash) or an
Acuson 128 XP scanner (Acuson, Mountain View,
Calif). Vein patency, the presence of acute or chronic
thrombotic change, luminal diameter, and location of
tributaries were recorded. Structures routinely imaged
included the cephalic, basilic, median cubital, brachial,
axillary, subclavian, jugular, and inominate veins.
In the NML and REDO/DVO groups, inflow
and outflow vessels were chosen on the basis of clin-
ical examination. In general, attempts were made to
use superficial veins located distally on the arm to
preserve proximal access sites. In the MAP/DVO
group, target veins were selected on the basis of
direct continuity with the axillary or subclavian
vein, a transverse view luminal diameter of 4 mm or
greater, and no evidence of thrombotic change.
Brachial, axillary, or subclavian venous anastomoses
constituted deep venous outflow; all other sites
were defined as superficial. Each procedure was per-
formed in an operating room after administration of
either general or local anesthetic through use of a
standard technique. In all but two cases, conduits
were made of 6-mm polytetrafluoroethylene; the
exceptions were a single 8-mm graft used in a
MAP/DVO patient and two tapered 4- to 6-mm
grafts, one used in a MAP/DVO patient and the
other used in an NML patient.
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Table III. Primary patency for NML, MAP/DVO, and REDO/DVO groups
No. of grafts at No. of grafts No. of grafts Interval Cumulative
Interval risk at beginning failed during withdrawn failure patency
(mo) of interval interval during interval rate rate SE
NML
0-1 64 4 1 0.063 93.7 2.9
1-3 59 11 2 0.190 75.9 4.9
3-6 46 6 1 0.132 65.9 5.7
6-9 39 3 1 0.078 60.8 6.1
9-12 35 2 3 0.060 57.2 6.3
12-15 30 2 7 0.075 52.8 6.6
15-18 21 1 5 0.054 50.0 7.7
18-21 15 2 0 0.133 43.3 8.4
21-24 13 1 3 0.087 39.6 8.5
24-27 9 0 1 0.000 39.6 10.3
MAP/DVO
0-1 35 4 1 0.116 88.4 5.1
1-3 30 1 1 0.034 85.4 6.0
3-6 28 6 2 0.222 66.4 7.3
6-9 20 3 5 0.171 55.0 8.3
9-12 12 3 1 0.261 40.7 9.1
12-15 8 1 0 0.125 35.6 10.1
15-18 7 1 1 0.154 30.1 9.5
18-21 5 0 1 0.000 30.1 11.3
21-24 2 0 3 0.000 30.1 17.8
24-27 1 0 1 0.000 30.1 25.2
REDO/DVO
0-1 16 5 0 0.313 68.8 9.6
1-3 11 2 0 0.182 56.3 11.2
3-6 9 2 0 0.222 43.8 10.9
6-9 7 0 0 0.000 43.8 12.4
9-12 7 1 0 0.143 37.5 11.2
12-15 6 1 1 0.182 30.7 10.4
15-18 4 2 0 0.500 15.3 7.1
18-21 2 0 0 0.000 15.3 10.0
21-24 2 0 1 0.000 15.3 10.0
24-27 1 0 0 0.000 15.3 14.1
Statistical analysis. Life tables were created in
accord with the revised recommendations of the Ad
Hoc Committee on Reporting Standards for the
Society for Vascular Surgery/International Society
for Cardiovascular Surgery. Life table primary and
secondary patency rates for NML, REDO/DVO,
and MAP/DVO were calculated and compared by
means of log-rank analysis. Intergroup comparisons
of proportional data were done with χ2 analysis.
Differences were considered significant if the P value
was less than .05.
RESULTS
Graft configuration. Upper extremity grafts
were preferentially placed in the nondominant arm.
There were four lower extremity AVBGs. The
brachial artery served as the most common source of
inflow and was used in 59 NML cases, 32
MAP/DVO cases, and all 16 REDO/DVO cases.
Other inflow arteries included the radial (n = 3),
ulnar (n = 1), common femoral (n = 1), and super-
ficial femoral (n = 3). Venous outflow tracts were the
median cubital, axillary, basilic, brachial, cephalic,
and common femoral veins. Outflow tracts used in
conjunction with brachial artery inflow are shown in
Table II. For the NML group, two other sources of
inflow were used: the radial artery was paired with
the basilic vein twice, and the superficial femoral
artery was paired with the common femoral vein
three times. For the MAP/DVO group, there were
three other combinations of inflow and outflow:
radial artery and median cubital vein, ulnar artery
and basilic vein, and common femoral artery and
common femoral vein. In all, the superficial venous
outflow tract was used in 83% of NML cases, 54% of
MAP/DVO cases, and 63% of REDO/DVO cases.
Patency. The rates of primary patency at 6
months for the NML group (65.9% ± 5.7%) and the
MAP/DVO group (66.4% ± 7.3%) were equivalent
(Fig 1 and Table III). Because of the small sample
size, the primary patency for the REDO/DVO
group (43.8% ± 10.9%) was not statistically signifi-
cantly less. The 6-month secondary patency rates for
the NML group (91.9% ± 3.4%) and the
MAP/DVO group (91.1% ± 4.9%) were equivalent
and were both significantly better than the patency
rate for the REDO/DVO group (75.0% ± 10.0%; P
= .004 for NML vs REDO/DVO and P = .04 for
MAP/DVO vs REDO/DVO; Fig 2 and Table IV).
MAP/DVO and REDO/DVO AVBGs made
significantly greater use of deep venous outflow
(46% and 37%, respectively) than did NML AVBGs
(17%). In the MAP/DVO group, the primary and
secondary patency rates for AVBGs anastomosed to
superficial veins were comparable to those for grafts
with deep vein outflow (Figs 3 and 4; Tables V and
VI). In addition, in the MAP/DVO group, all
AVBG revisions remained in the original venous sys-
tem division, with no superficial-to-deep or deep-to-
superficial modifications.
DISCUSSION
Recent advances in angioaccess surgery have
focused on increasing the use of autogenous arterio-
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Fig 4. Secondary patencies for superficial vein versus deep vein outflow in MAP/DVO group.
venous fistulae and thus on improving angioaccess
durability.9 Duplex sonography has been used to
guide the selection of arterial inflow and venous out-
flow for these fistulae with success.9,12,22
Unfortunately, even with optimal scanning, up to 30%
of patients will require AVBGs.9 The increasing inci-
dence of end-stage renal disease, both over all and
with age, and the relative growth of the elderly seg-
ment of the population combine to create a sustained
need for AVBGs.23-25 Improved durability of AVBGs
may therefore have a significant effect on life
expectancy in the dialysis population. We hypothe-
sized that duplex-directed AVBG creation would pro-
vide increases in graft durability similar to those
observed with autogenous fistulae. Mapped patients
with clinical evidence of DVO (MAP/DVO) were
compared with two unmapped control groups: one
with clinically presumed normal venous outflow
(NML-first AVBG) and the other with clinically
proven DVO (REDO/DVO-second AVBG in an
ipsilateral extremity). Although primary patency rates
were not statistically significantly less at 6 months,
presumably because of the small sample size, the
mean patency rate for the REDO/DVO group
(43.8%) was lower than the similar patency rates for
the NML (65.9%) and MAP/DVO (66.4%) groups.
However, secondary patency in the MAP/DVO
group (91.1%) was significantly better than that in the
REDO/DVO group (75.0%) and equivalent to that
in the NML group (91.9%). These relative differences
persisted beyond 12 months in mean values, but sta-
tistical significance was lost. In comparison with the
NML group, both the REDO/DVO and MAP/
DVO groups had proportionally more anastomoses
to the deep venous system. There was, however, no
difference in patency (primary or secondary) between
MAP/DVO AVBGs directed into deep veins and
MAP/DVO AVBGs directed into superficial veins.
These findings demonstrate that preoperative venous
duplex scanning examination is a useful tool that can
enhance AVBG durability in patients with clinical evi-
dence of disadvantaged venous runoff.
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Table IV. Secondary patency for NML, MAP/DVO, and REDO/DVO groups
No. of grafts at No. of grafts No. of grafts Interval Secondary
Interval risk at beginning failed during withdrawn failure patency
(mo) of interval interval during interval rate rate SE
NML
0-1 64 2 1 0.031 96.9 2.2
1-3 61 1 2 0.017 95.2 2.7
3-6 58 2 2 0.035 91.9 3.4
6-9 54 0 3 0.000 91.9 3.6
9-12 51 0 4 0.000 91.9 3.7
12-15 47 1 14 0.025 89.6 4.2
15-18 32 3 8 0.107 80.0 6.3
18-21 21 0 2 0.000 80.0 7.8
21-24 19 1 4 0.059 75.3 8.6
24-27 14 0 1 0.000 75.3 10.0
MAP/DVO
0-1 35 2 1 0.058 94.2 3.8
1-3 32 0 1 0.000 94.2 4.0
3-6 31 1 2 0.033 91.1 5.0
6-9 28 0 6 0.000 91.1 5.1
9-12 22 1 2 0.048 86.7 6.7
12-15 19 0 1 0.000 86.7 7.3
15-18 18 2 4 0.125 75.9 8.8
18-21 12 0 5 0.000 75.9 10.8
21-24 7 0 4 0.000 75.9 14.1
24-27 3 0 3 0.000 75.9 21.5
REDO/DVO
0-1 16 1 0 0.063 93.8 5.9
1-3 15 1 0 0.067 87.5 8.0
3-6 14 2 0 0.143 75.0 10.0
6-9 12 1 0 0.083 68.8 11.1
9-12 11 1 0 0.091 62.5 11.5
12-15 10 0 1 0.000 62.5 12.1
15-18 9 2 3 0.267 45.8 11.2
18-21 4 0 2 0.000 45.8 16.9
21-24 2 0 1 0.000 45.8 23.9
24-27 1 0 0 0.000 45.8 33.7
The principles that guide the construction of
arteriovenous fistulae have been developed during
three decades of experience. Early reports docu-
mented autogenous fistula patency rates of 60% to
90% at 12 months and noted poor graft salvage with
early failure.4,7,13 Kinnaert et al16 identified vein size
as a factor contributing to autogenous fistulae failure
in 1977. Reilly et al18 suggested that prior failed
autogenous fistulae may eliminate usable veins and
thus adversely affect subsequent forms of access.
After the introduction of AVBGs, Tordoir et al17,26
noted enhanced durability with primary autogenous
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Table V. Primary patency for superficial vein versus deep vein outflow in MAP/DVO group
No. of grafts at No. of grafts No. of grafts Interval Secondary
risk at beginning failed during withdrawn failure patency
Interval (mo) of interval interval during interval rate rate (%) SE (%)
Superficial vein outflow
0-1 20 2 0 0.100 90.0 6.4
1-3 18 1 0 0.056 85.0 7.8
3-6 17 2 1 0.121 74.7 9.1
6-9 14 1 4 0.083 68.5 10.3
9-12 9 1 0 0.111 60.9 12.7
12-15 8 1 0 0.125 53.3 12.9
15-18 7 1 1 0.154 45.1 12.6
18-21 5 0 1 0.000 45.1 14.9
21-24 4 0 3 0.000 45.1 16.7
24-27 1 0 1 0.000 45.1 33.4
Deep vein outflow
0-1 15 2 1 0.138 86.2 8.3
1-3 12 0 1 0.000 86.2 9.2
3-6 11 4 0 0.364 54.9 11.1
6-9 7 2 2 0.333 36.6 11.0
9-12 3 2 1 0.800 7.3 4.1
12-15 0 0 0 – – –
15-18 0 0 0 – – –
18-21 0 0 0 – – –
21-24 0 0 0 – – –
24-27 0 0 0 – – –
Table VI. Secondary patency for superficial vein versus deep vein outflow in MAP/DVO group
No. of grafts at No. of grafts No. of grafts Interval Secondary
risk at beginning failed during withdrawn failure patency
Interval (mo) of interval interval during interval rate rate (%) SE (%)
Superficial vein outflow
0-1 20 1 0 0.050 95.0 4.8
1-3 19 0 0 0.000 95.0 4.9
3-6 19 0 2 0.000 95.0 4.9
6-9 17 0 4 0.000 95.0 5.2
9-12 13 1 0 0.077 87.7 8.5
12-15 12 0 0 0.000 87.7 8.9
15-18 12 1 2 0.091 79.7 10.4
18-21 9 0 3 0.000 79.7 12.0
21-24 6 0 4 0.000 79.7 14.7
24-27 2 0 2 0.000 79.7 25.4
Deep vein outflow
0-1 15 1 1 0.069 93.1 6.3
1-3 13 0 1 0.000 93.1 6.8
3-6 12 1 0 0.083 85.3 9.4
6-9 11 0 2 0.000 85.3 9.9
9-12 9 0 2 0.000 85.3 10.9
12-15 7 0 1 0.000 85.3 12.4
15-18 6 1 2 0.200 68.3 15.7
18-21 3 0 2 0.000 68.3 22.2
21-24 1 0 0 0.000 68.3 38.5
24-27 1 0 1 0.000 68.3 38.5
fistulae in comparison with secondary prosthetic
AVBGs. Munda et al27 further emphasized that a
67% 12-month secondary patency for prosthetic
angioaccess could be expected only for the forearm
loop configuration and was associated with an 80%
complication rate as a result of thrombosis, intimal
hyperplasia, or infection. In contrast, Palder et al7
suggested that an aggressive revision strategy for
AVBGs could produce improved long-term patency
in AVBGs in comparison with autologous fistulae.7
Our philosophy of AVBG construction reflected
these opinions and in the NML group resulted in
primary and secondary 12-month patency rates of
57% and 91.9%, respectively—comparable to those
in the aforementioned reports.
The concept of DVO goes hand-in-hand with the
placement of an AVBG. Most AVBG studies imply a
history of venous injury in that clinical evidence of
poor superficial venous anatomy or prior failed
hemodialysis access is the indication for AVBG cre-
ation.13-15,17,19,20,26 Poor durability in subsequent
AVBGs after failed autogenous or prosthetic fistulae,
as reported by Chazan et al5 and Hodges et al,14 is
consistent with the theory that prior angioaccess may
reduce venous runoff. Our REDO/DVO patients all
had prior failed autogenous fistulae or AVBGs that
were replaced with completely new AVBGs in the
ipsilateral extremity. The trend in this group toward
markedly reduced primary and secondary patency
(32.5% and 62.5%, respectively) is indirect evidence
of venous destruction and is in agreement with the
results of other investigators.4,10,14,15,27
Venous runoff suitable for creation of a durable
arteriovenous fistula is dependent on the simple
exposure of a vessel, the vessel’s size, and the direct
continuity of the vessel with the central venous sys-
tem. In 1986, Kerlakian et al13 first suggested that
B-mode ultrasound scanning might provide useful
guidance in venous outflow selection. In 1997, Silva
et al9,12 systematically applied preoperative duplex
scanning to guide the creation of arteriovenous fis-
tulae, stressing anastomotic continuity with the cen-
tral venous system. They achieved significant
increases in autogenous fistula utilization and
reduced early failure rates while creating 53% of
these accesses in clinically unsuitable upper extremi-
ties. When prosthetic grafts were necessary, venous
outflow, directed into either antecubital or axillary
veins, provided excellent patency rates, suggesting
the utility of the deep system for outflow. The spar-
ing of the deep venous system in limbs with disad-
vantaged venous runoff is demonstrated by the fact
that significantly more AVBGs were directed into
deep veins in the DVO group than in the NML
group. The absence of AVBG revision from superfi-
cial-to-deep veins and vice versa in mapped extremi-
ties is explained by a conscious bias toward initial
utilization of distal, marginal veins. More important,
the equivalent secondary durabilities of AVBGs
placed into either deep or superficial veins suggests
that in the limb with disadvantaged venous runoff,
the ultimate significance of mapping lies in the iden-
tification of direct continuity with the central venous
system. Accordingly, optimal AVBG longevity may
best be achieved when early AVBG placement to
deep veins is performed only when mapping demon-
strates the absence of superficial veins in direct con-
tinuity with the central venous system.
This study confirms assumptions made in previ-
ous angioaccess reports and provides observations
regarding improved AVBG durability. Direct duplex
evidence demonstrates that superficial veins are trau-
matized by prior AVBG and multiple venipunctures,
in that significantly more DVO grafts than NML
grafts were directed into the deep system. Life table
evidence indicates that preoperative vein mapping
can enhance the durability of AVBGs in the DVO
extremity. A shortcoming of the small REDO/DVO
group size was that a statistically significant difference
could not be demonstrated for secondary patency
beyond 6 months. Finally, indirect evidence, consist-
ing of equivalent patencies in mapped grafts directed
to either superficial or deep veins and no revisions of
grafts from superficial-to-deep or vice versa, suggests
that the value of vein mapping in the DVO extremi-
ty lies in the identification of continuity between the
venous anastomosis and the central venous system.
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